Navigation Links
Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
Date:1/25/2008

SAN DIEGO, Jan. 25 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Merck & Co., Inc. initiated a Phase 1 clinical trial of a second generation oral niacin receptor agonist under a collaboration between the companies to discover drugs for the treatment of atherosclerosis and other disorders. The initiation of this trial does not trigger a milestone payment.

"We are very pleased with the progress of this collaboration investigating the therapeutic potential of niacin receptor agonists to treat atherosclerosis and other disorders. We are looking forward to the Phase 1 results and the continued progress of the program," said Jack Lief, Arena's President and Chief Executive Officer.

Arena also announced that preclinical investigation of MK-0354, a first generation niacin receptor agonist being evaluated for indications other than atherosclerosis, was discontinued for compound specific reasons.

About Atherosclerosis

Atherosclerosis is characterized by the collection of fatty material deposits, such as cholesterol, along artery walls. This fatty material thickens, hardens, and may eventually block the arteries, adversely affecting blood flow and increasing the risk of heart attack and stroke over time. The American Heart Association estimates that atherosclerosis accounts for nearly 75% of all deaths from cardiovascular disease. HDL cholesterol, commonly known as the "good" cholesterol, can help clear the fatty deposits from the walls of blood vessels and transport cholesterol to the liver for processing and removal from the body. Drugs that can influence the levels of HDL cholesterol, or "good" cholesterol, may potentially provide clinical benefits to patients by reducing the
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
2. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
3. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
4. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
9. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
10. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
11. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... of rod-shaped metal nanoparticles in water with ultrasound and ... bits. Why? No one yet knows exactly. But researchers ... have clocked their speedand it,s fast. At up to ... faster than any nanoscale object submerged in liquid ever ... opened up the possibility that they could be used ...
(Date:7/22/2014)... 2014   BioTE Medical , a leading ... hormone pellets, today announced the addition of Dr. ... Dr. Rouzier is joining the BioTE Medical Advisory ... Dr. Rouzier was residency trained in Family Medicine ... board certified emergency physician still practicing at a ...
(Date:7/22/2014)... CTD Holdings, Inc. (OTCQB:CTDH), a manufacturer and distributor ... other markets, announced today that it has closed on ... investors led by Novit L.P., an investment arm of ... the signing of a Securities Purchase Agreement under which ... a price per share of $1.00, resulting in a ...
(Date:7/22/2014)... 2014 Rice Lake Weighing ... 2014 NCSL International Workshop and Symposium July 28-31 ... CONDEC pressure instrumentation, OIML M1 weights, precision lab ... customized sets, Essential Weights™. , NCSL International was ... in solving the common problems faced by measurement ...
Breaking Biology Technology:NIST shows ultrasonically propelled nanorods spin dizzyingly fast 2Dr. Neal Rouzier Joins BioTE Medical 2Dr. Neal Rouzier Joins BioTE Medical 3CTD Holdings Closes $1.725 Million Private Placement 2CTD Holdings Closes $1.725 Million Private Placement 3Rice Lake Weighing Systems Showcases Metrology Solutions for the 2014 NCSL International Workshop & Symposium 2
... (Nasdaq: EXEL ) announced today that George A. ... present at the Goldman Sachs,29th Annual Global Healthcare Conference ... 2008. Dr. Scangos will discuss updates to the company,s,development ... webcast and may be accessed in the Event,Calendar page ...
... - Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ... today announced the completion of U.S. clinical,trial enrolment ... "Our proprietary Bio-Seal product represents a potentially ... cancer," said Dr.,William Hunter, President and CEO of ...
... Corporation and,ATEL Ventures, Inc., today announced they have ... a privately held, venture-backed life,science company., AxoGen ... nerve repair. Their,patented product, AVANCE(TM) Nerve Graft is ... and regeneration of peripheral nerves., "Oxford,s and ...
Cached Biology Technology:Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment 2Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment 3Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment 4Oxford Finance Corporation and ATEL Ventures, Inc. Provide $7.5 Million Venture Loan to AxoGen, Inc. 2
(Date:7/22/2014)... New research from the Monell Center reveals that simply ... airway inflammation in asthmatics for at least 24 hours ... can play in health-related outcomes. , "Asthmatics often are ... an odor is harmful, our bodies react as if ... Cristina Jan, PhD, a Monell physiologist. "Both patients and ...
(Date:7/22/2014)... 2014, by lightning from a weather system that moved through ... Stokes Fire, Gold Hikes Fire, French Creek Fire and the ... one larger fire. The fires are burning in timber and ... in size. The present fire situation continues to rapidly ... safety is the priority on the Carlton Complex fires. ...
(Date:7/22/2014)... Health Policy and Economics have linked tighter Medicaid ... for schizophrenic individuals. , The study comes amid ... actually save money, when other costs are taken ... extra approval step before tests or treatments can ... prior authorization is intended to encourage physicians ...
Breaking Biology News(10 mins):In asthma, it's not just what you smell, but what you think you smell 2In asthma, it's not just what you smell, but what you think you smell 3Are state Medicaid policies sentencing people with mental illnesses to prison? 2
... designed to block cat allergies successfully prevented allergic reactions ... in a test tube, University of California, Los Angeles ... Medicine, available online now. In the future, the investigators ... therapy not only for human cat allergies, but also ...
... scientists have found,that bacteria can use a Sonar-like ... or other bacteria) and target them for destruction.,Reported ... finding explains how,some bacteria know when to produce ... lead to the design of new toxin inhibitors. ...
... Patent # 6,872,552, "A Method of Reconstituting Nucleic Acid ... MatrixDesign, and CEO of DermaPlus, Inc. The patent covers ... samples, and could allow scientists to reassemble everything from ... discovery, when properly applied by our scientists, brings us ...
Cached Biology News:Novel Therapy Tested in Mice Could Chase Away Cat Allergies 2Novel Therapy Tested in Mice Could Chase Away Cat Allergies 3Antibiotic Resistant Bacterium Uses Sonar-like Strategy to “See?Enemies or Prey 2Dinosaur DNA? New Patent Covers Degraded DNA recovery 2
TMB Slow Kinetic One Component HRP Microwell Substrate, 1 L...
Eppendorf tube holder, for Tube rack 175 x 12 mm, 100. Category: Chromatography Systems & Accessories, Systems....
Pooled normal sreum with 0.1% sodium azide as preservative...
Agarose, pulse field, 250 g. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1800 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Biology Products: